Tabriz University of Medical Sciences Pharmaceutical Sciences 1735-403X 29 1 2023 01 01 The Impact of Metformin on Cardiac Troponin-I and ST Resolution in Patients with ST Elevation Myocardial Infarction Undergoing Thrombolytic Therapy 59 64 10.34172/PS.2022.10 EN Naser Aslanabadi https://orcid.org/0000-0003-2274-1494 Samineh Beheshtirouy https://orcid.org/0000-0002-6634-2105 Sina Mashayekhi Zahra Heidari Sana Hamedani Taher Entezari-Maleki https://orcid.org/0000-0003-3653-3653 Journal Article 10.34172/PS.2022.10 2021 10 14 2022 02 27 Background: Thrombolytic therapy is a key in the management of ST elevated myocardial infarction (STEMI). Metformin implies a series of cardioprotective effects. We aimed to investigate how pretreatment with metformin could affect cardiac troponin I (cTnI) levels following reteplase therapy amid STEMI patients. Methods: A pilot randomized clinical trial was carried out in 80 STEMI patients undergoing thrombolytic therapy with reteplase. The metformin group (n = 40) received a single dose of 1000 mg metformin orally before receiving reteplase, while the control group (n = 40) received only reteplase. The serum level of cTnI was measured at baseline, 8, 16, 24, and 32 hours after the admission to assess myocardial damage. Results: There was no significant difference in cTnI levels at baseline (p = 0.657), 8 (p = 0.93), 16 (p = 0.690), 24 (p = 0.217), and 32 (p = 0.517) hours after STEMI diagnosis between two groups. The mean differences were also not significant for changes of cTnI at baseline and other time frames. Conclusion: The results of the present study demonstrated that early use of 1000 mg metformin prior to reteplase could not reduce the level of cTnI in STEMI patients.